Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
Researchers reviewed the fast-growing interest in psychedelic therapies. They found that even though hundreds of studies are under way, no psychedelic medicine is officially approved for any mental health condition yet. The review explains the kinds of drugs being tested, the conditions people hope to treat, and big challenges such…
